Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases - 1 Oct 2007

Ajroud-Driss Senda, Saeed Mohammad, Khan Humaira, Siddique Nailah, Hung W Y, Sufit Robert, Heller Scott, Armstrong Jennifer, Casey Pat, Siddique Teepu, Lukas Thomas J

Abstract excerpt

Riluzole is the only FDA approved drug for the treatment of amyotrophic lateral sclerosis. Riluzole is assumed to be mainly metabolized by the liver cytochrome CYP1A2 and by the extra-hepatic cytochrome CYP1A1. CYP1A2 and CYP1A1 genetic polymorphisms are known, but their relationship to riluzole metabolism in ALS patients has not been investigated. The aim of this study was to determine whether the polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to Chromatography, High Pressure Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 5

Share to Cytochrome P-450 CYP1A1

Share to Cytochrome P-450 CYP1A2

Share to Mass Spectrometry

Share to Neuroprotective Agents

Share to Pharmacogenetics

Source

Identifiers

PMID: 17852022
DOI: 10.1080/17482960701500650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.PMID 17852022Read ↗

Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.Semantic proximity Read ↗

Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.Semantic proximity Read ↗

CYP2D6 variants in amyotrophic lateral sclerosis: an association study of risk and survivalSemantic proximity Read ↗

Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.Semantic proximity Read ↗

The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.Semantic proximity Read ↗

Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects.Semantic proximity Read ↗

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.Semantic proximity Read ↗

No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.Semantic proximity Read ↗

Evaluation of Clinical Outcomes of Riluzole monotherapy and Riluzole based adjunctive interventions in Amyotrophic Lateral Sclerosis: A meta-analytic and unsupervised clustering approachSemantic proximity Read ↗

Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil.Semantic proximity Read ↗

Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction.Semantic proximity Read ↗

CYP1A2*F Polymorphism Contributes at Least Partially to the Variability of Plasma Levels of Dehydroaripiprazole, an Active Metabolite of Aripiprazole, in Schizophrenic Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.